The role of electronegative low-density lipoprotein in cardiovascular diseases and its therapeutic implications
| Autor: | Ferah Armutcu, Chu-Huang Chen, Jonathan Lu, Liang-Yin Ke, Sumeyya Akyol, Fatih Akçay, Omer Akyol |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Electronegative low-density lipoprotein business.industry Disease 030204 cardiovascular system & hematology Scavenger Receptors Class E Up-Regulation Lipoproteins LDL 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Cardiovascular Diseases Risk Factors Immunology Humans Medicine Cardiology and Cardiovascular Medicine business Biomarkers Dyslipidemias Hypolipidemic Agents Signal Transduction Lipoprotein |
| Zdroj: | Trends in Cardiovascular Medicine. 27:239-246 |
| ISSN: | 1050-1738 |
| DOI: | 10.1016/j.tcm.2016.11.002 |
| Popis: | Cardiovascular disease (CVD) is a health problem of great concern to both the public and medical authorities. Low-density lipoprotein (LDL) has been reported to play an important role in both the development and progression of CVD, but studies are underway to determine how LDL exerts its effects. In recent years, it has been found that LDL has several subfractions, each of which affects endothelial function differently; L5, the most electronegative fraction, has been shown to be unique in that it induces an atherogenic response. This review examines the current knowledge concerning the relationships between L5 and CVD and highlights the role of L5 in the pathophysiology of CVD, especially with regards to atherosclerosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect